OncoSec Announces Exclusive License Agreement for Cliniporator® Gene Electrotransfer Platform Developed by IGEA Clinical Biophysics Nov 24, 2020 9:00am EST
OncoSec Provides Highlights from Analyst & Investor Day and SITC 2020 and Announces KEYNOTE-695 Reaches Full Enrollment Nov 18, 2020 9:00am EST
OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020 Nov 09, 2020 8:36am EST
OncoSec Hosting an Investor and Analyst Day Webinar Showcasing Positive KEYNOTE-695 Data in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma Nov 05, 2020 9:00am EST
OncoSec to Present Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020 Nov 03, 2020 9:00am EST
OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1 Clinical Trial of its CORVax12 Vaccine Candidate for COVID-19 Oct 29, 2020 9:10am EDT
OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer Oct 12, 2020 8:30am EDT
OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO™ and Its Gene Delivery Platform Oct 06, 2020 8:30am EDT
OncoSec Announces Initiation of a Phase 2 Study at the Moffitt Cancer Center to Evaluate the Combination of TAVO plus OPDIVO® as Neoadjuvant Therapy for Melanoma Aug 27, 2020 8:30am EDT
